TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis
Brief Summary: The primary objective of the study was to assess the effect of two doses of teriflunomide, in comparison to placebo, on the frequency of multiple sclerosis (MS) relapses in participants with relapsing MS.

Key secondary objective was to assess the effect of the two doses of teriflunomide, in comparison to placebo, on disability progression.

Other secondary objectives were:

* To assess the effect of the two doses of teriflunomide in comparison to placebo on:

  * Fatigue;
  * Health-related quality of life, a measure of the impact of the participant's health on his or her overall well being.
* To evaluate the safety and tolerability of teriflunomide.


Options:
A: Arm Label: Teriflunomide 7 mg / 14 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: Teriflunomide 14 mg / 14 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: IFN-β-1a / 14 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon β-1a, Drug: Teriflunomide | Intervention Type: DRUG; Name: Interferon β-1a; Assigned to Arm(s): IFN-β-1a / 14 mg | Intervention Type: DRUG; Name: Teriflunomide; Assigned to Arm(s): IFN-β-1a / 14 mg, Teriflunomide 14 mg / 14 mg, Teriflunomide 7 mg / 14 mg
B: Arm Label: Placebo/Teriflunomide 7 mg or Teriflunomide 14 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: Teriflunomide, Drug: Placebo | Arm Label: Teriflunomide 7 mg/7 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: Teriflunomide 14 mg/14 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Intervention Type: DRUG; Name: Teriflunomide; Assigned to Arm(s): Placebo/Teriflunomide 7 mg or Teriflunomide 14 mg, Teriflunomide 14 mg/14 mg, Teriflunomide 7 mg/7 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo/Teriflunomide 7 mg or Teriflunomide 14 mg
C: Arm Label: Teriflunomide 7 mg; Type: EXPERIMENTAL; Interventions: Drug: teriflunomide (HMR1726) | Arm Label: Teriflunomide 14 mg; Type: EXPERIMENTAL; Interventions: Drug: teriflunomide (HMR1726) | Intervention Type: DRUG; Name: teriflunomide (HMR1726); Assigned to Arm(s): Teriflunomide 14 mg, Teriflunomide 7 mg
D: Arm Label: Teriflunomide 7 mg / 14 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: Teriflunomide 14 mg / 14 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: Placebo / Teriflunomide 14 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Teriflunomide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo / Teriflunomide 14 mg | Intervention Type: DRUG; Name: Teriflunomide; Assigned to Arm(s): Placebo / Teriflunomide 14 mg, Teriflunomide 14 mg / 14 mg, Teriflunomide 7 mg / 14 mg

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis
Brief Summary: The primary objective of the study was to assess the effect of two doses of teriflunomide, in comparison to placebo, on the frequency of multiple sclerosis (MS) relapses in participants with relapsing MS.

Key secondary objective was to assess the effect of the two doses of teriflunomide, in comparison to placebo, on disability progression.

Other secondary objectives were:

* To assess the effect of the two doses of teriflunomide in comparison to placebo on:

  * Fatigue;
  * Health-related quality of life, a measure of the impact of the participant's health on his or her overall well being.
* To evaluate the safety and tolerability of teriflunomide.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Cyclophosphamide (drug) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylprednisolone (drug) | Intervention Type: DRUG; Name: Cyclophosphamide (drug); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Methylprednisolone (drug); Assigned to Arm(s): 2
B: Arm Label: Placebo + GA; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for teriflunomide), Drug: Glatiramer Acetate (GA) | Arm Label: Teriflunomide 7 mg + GA; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide, Drug: Glatiramer Acetate (GA) | Arm Label: Teriflunomide 14 mg + GA; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide, Drug: Glatiramer Acetate (GA) | Intervention Type: DRUG; Name: Teriflunomide; Assigned to Arm(s): Teriflunomide 14 mg + GA, Teriflunomide 7 mg + GA | Intervention Type: DRUG; Name: Placebo (for teriflunomide); Assigned to Arm(s): Placebo + GA | Intervention Type: DRUG; Name: Glatiramer Acetate (GA); Assigned to Arm(s): Placebo + GA, Teriflunomide 14 mg + GA, Teriflunomide 7 mg + GA
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: BG00012 240 mg Twice Daily (BID); Type: EXPERIMENTAL; Interventions: Drug: BG00012 | Arm Label: BG00012 240 mg 3 Times Daily (TID); Type: EXPERIMENTAL; Interventions: Drug: BG00012 | Intervention Type: DRUG; Name: BG00012; Assigned to Arm(s): BG00012 240 mg 3 Times Daily (TID), BG00012 240 mg Twice Daily (BID) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Teriflunomide 7 mg / 14 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: Teriflunomide 14 mg / 14 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: Placebo / Teriflunomide 14 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Teriflunomide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo / Teriflunomide 14 mg | Intervention Type: DRUG; Name: Teriflunomide; Assigned to Arm(s): Placebo / Teriflunomide 14 mg, Teriflunomide 14 mg / 14 mg, Teriflunomide 7 mg / 14 mg

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of the HeartWare Left Ventricular Assist Device for the Treatment of Advanced Heart Failure
Brief Summary: The purpose of this study is to evaluate the safety and effectiveness of the HeartWare® LVAD System in patients listed for cardiac transplantation with refractory, advanced heart failure at risk of death. The primary endpoint is survival at 180 days which is defined as alive on the originally implanted HeartWare® LVAD or transplanted or explanted for recovery. Patient must survive 60 days post-explant for recovery to be considered successful. Secondary endpoints include:

* Overall survival
* Incidence of all serious adverse events, neurocognitive status and unanticipated adverse device effects.
* Incidence of all device failures and device malfunctions
* Quality of Life improvement, as measured by Kansas City Cardiomyopathy Questionnaire (KCCQ) and EuroQoL EQ-5D
* Functional status improvement, as measured by the New York Heart Association (NYHA) and 6-minute walk

The HeartWare® LVAD System was approved by the US FDA on November 20, 2012 as a bridge to cardiac transplantation (reference PMA P100047). Patients enrolled into this study will be followed to an outcome at six months, and then patients will receive continued follow-up in a separate study.


Options:
A: Intervention Type: BEHAVIORAL; Name: exercise training; Assigned to Arm(s): N/A
B: Arm Label: HeartWare® VAS; Type: EXPERIMENTAL; Interventions: Device: HeartWare® VAS | Intervention Type: DEVICE; Name: HeartWare® VAS; Assigned to Arm(s): HeartWare® VAS
C: Arm Label: AIT: aerobic interval training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Aerobic interval training | Arm Label: MIT, moderate intensity training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: moderate intensity training | Arm Label: Recommendation of regular exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Recommendation of regular exercise | Intervention Type: BEHAVIORAL; Name: Aerobic interval training; Assigned to Arm(s): AIT: aerobic interval training | Intervention Type: BEHAVIORAL; Name: moderate intensity training; Assigned to Arm(s): MIT, moderate intensity training | Intervention Type: BEHAVIORAL; Name: Recommendation of regular exercise; Assigned to Arm(s): Recommendation of regular exercise
D: Arm Label: Basic Pedometry Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Basic Intervention | Arm Label: Enhanced Pedometry Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced Pedometry | Arm Label: Control Group; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Control Group | Intervention Type: BEHAVIORAL; Name: Basic Intervention; Assigned to Arm(s): Basic Pedometry Intervention | Intervention Type: BEHAVIORAL; Name: Enhanced Pedometry; Assigned to Arm(s): Enhanced Pedometry Intervention | Intervention Type: BEHAVIORAL; Name: Control Group; Assigned to Arm(s): Control Group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Web-based Ultra-brief Intervention for Heavy Drinkers - a Randomized Controlled Trial Comparing Personalized Normative Feedback With Self-help Material
Brief Summary: The purpose of the study is to determine whether a web-based ultra-brief intervention, consisting of personalized normative feedback or standardized self-help material, is effective in lowering self reported alcohol use in heavy drinkers.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Brief intervention based on motivational interviewing | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard Care including referral for treatment | Intervention Type: BEHAVIORAL; Name: Brief intervention based on motivational interviewing; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Standard Care including referral for treatment; Assigned to Arm(s): 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Personalised normative feedback (PNF) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Other: Self-help material | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Other: Control | Intervention Type: OTHER; Name: Personalised normative feedback (PNF); Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Self-help material; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): 3
C: Arm Label: Brief Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Enhancement Therapy | Arm Label: Assessed Control Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: No Contact Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Motivational Enhancement Therapy; Assigned to Arm(s): Brief Intervention Group
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Adapted Motivational Interviewing & Skills Training | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Adapted Motivational Interviewing & Skills Training | Arm Label: 3; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Adapted Motivational Interviewing & Skills Training; Assigned to Arm(s): 1, 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: VITA-D: Cholecalciferol Substitution in Vitamin D Deficient Kidney Transplant Recipients: A Randomized, Placebo-controlled Study to Evaluate the Posttransplant Outcome
Brief Summary: The purpose of the study is to evaluate the effects of Cholecalciferol (Vitamin D3) substitution on the posttransplant outcome (glomerular filtration rate as well as serum creatinine levels, number of acute rejection episodes, number of infections and C-reactive protein levels within the first year after transplantation) in vitamin D deficient kidney transplant recipients.


Options:
A: Arm Label: Postassium citrate; Type: EXPERIMENTAL; Interventions: Drug: Potassium citrate | Arm Label: Potassium chloride; Type: ACTIVE_COMPARATOR; Interventions: Drug: Potassium chloride | Intervention Type: DRUG; Name: Potassium citrate; Assigned to Arm(s): Postassium citrate | Intervention Type: DRUG; Name: Potassium chloride; Assigned to Arm(s): Potassium chloride
B: Arm Label: Parmidronate; Type: EXPERIMENTAL; Interventions: Drug: Pamidronate | Intervention Type: DRUG; Name: Pamidronate; Assigned to Arm(s): Parmidronate
C: Intervention Type: DRUG; Name: Cinacalcet HCl; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cholecalciferol | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Cholecalciferol; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Home Automated Telemanagement in COPD
Brief Summary: All chronic obstructive pulmonary diseases (COPDs) block air flow to the lungs, and the two most common forms, emphysema and chronic bronchitis, are the most common causes of respiratory failure. Previous research shows that if COPD patients know more about their disease and how to manage it themselves, they will improve their quality of life and reduce their need for urgent care. However, traditional methods of teaching COPD patients about their disease and self-management skills are expensive and require intensive work. A new, less expensive way of reaching a large group of people with this information is needed to help patients stay healthier and happier with their treatment. This study will create a computer program that can help people learn about their disease and how to manage it themselves. This study will then determine whether the computer program, called Home Automated Telemanagement (HAT), helps patients with COPD in managing their disease and following their treatment plans.


Options:
A: Arm Label: Traditional hospital-based PR; Type: ACTIVE_COMPARATOR; Interventions: Other: Hospital-based PR | Arm Label: Web-based PR; Type: EXPERIMENTAL; Interventions: Other: Web-based PR | Intervention Type: OTHER; Name: Web-based PR; Assigned to Arm(s): Web-based PR | Intervention Type: OTHER; Name: Hospital-based PR; Assigned to Arm(s): Traditional hospital-based PR
B: Arm Label: COPD Telehealth Program; Type: EXPERIMENTAL; Interventions: Behavioral: Telehealth Program | Intervention Type: BEHAVIORAL; Name: Telehealth Program; Assigned to Arm(s): COPD Telehealth Program
C: Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Coaching program; Type: EXPERIMENTAL; Interventions: Other: Coaching program | Intervention Type: OTHER; Name: Coaching program; Assigned to Arm(s): Coaching program
D: Arm Label: HAT; Type: EXPERIMENTAL; Interventions: Behavioral: Home Automated Telemanagement (HAT) | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Home Automated Telemanagement (HAT); Assigned to Arm(s): HAT

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Home Automated Telemanagement in COPD
Brief Summary: All chronic obstructive pulmonary diseases (COPDs) block air flow to the lungs, and the two most common forms, emphysema and chronic bronchitis, are the most common causes of respiratory failure. Previous research shows that if COPD patients know more about their disease and how to manage it themselves, they will improve their quality of life and reduce their need for urgent care. However, traditional methods of teaching COPD patients about their disease and self-management skills are expensive and require intensive work. A new, less expensive way of reaching a large group of people with this information is needed to help patients stay healthier and happier with their treatment. This study will create a computer program that can help people learn about their disease and how to manage it themselves. This study will then determine whether the computer program, called Home Automated Telemanagement (HAT), helps patients with COPD in managing their disease and following their treatment plans.


Options:
A: Arm Label: HAT; Type: EXPERIMENTAL; Interventions: Behavioral: Home Automated Telemanagement (HAT) | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Home Automated Telemanagement (HAT); Assigned to Arm(s): HAT
B: Arm Label: Tool + Self-management Support Program; Type: EXPERIMENTAL; Interventions: Device: Tool, Behavioral: Self-management Support Program | Arm Label: Self- management Support Program; Type: EXPERIMENTAL; Interventions: Behavioral: Self-management Support Program | Arm Label: Care as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Tool; Assigned to Arm(s): Tool + Self-management Support Program | Intervention Type: BEHAVIORAL; Name: Self-management Support Program; Assigned to Arm(s): Self- management Support Program, Tool + Self-management Support Program
C: Arm Label: COPD education + Usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: COPD education + Usual care | Arm Label: Physical activity self-management; Type: EXPERIMENTAL; Interventions: Behavioral: Physical activity self-management | Intervention Type: BEHAVIORAL; Name: Physical activity self-management; Assigned to Arm(s): Physical activity self-management | Intervention Type: OTHER; Name: COPD education + Usual care; Assigned to Arm(s): COPD education + Usual care
D: Arm Label: Case Management; Type: EXPERIMENTAL; Interventions: Behavioral: Case Management | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Case Management; Assigned to Arm(s): Case Management

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma
Brief Summary: This clinical trial will compare the efficacy and safety of the combination of AMG 386 and FOLFIRI with FOLFIRI alone in second line treatment of metastatic colorectal cancer.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: CPT-11 and TS-1 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: CPT-11, 5-FU and l-LV | Intervention Type: DRUG; Name: CPT-11 and TS-1; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: CPT-11, 5-FU and l-LV; Assigned to Arm(s): 2
B: Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: AMG 386 Placebo, Drug: FOLFIRI | Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: AMG 386, Drug: FOLFIRI | Intervention Type: DRUG; Name: AMG 386; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: AMG 386 Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: FOLFIRI; Assigned to Arm(s): 1, 2
C: Arm Label: TAS-102; Type: EXPERIMENTAL; Interventions: Drug: TAS-102 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: TAS-102; Assigned to Arm(s): TAS-102 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chemotherapy | Arm Label: Chemotherapy + Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Chemotherapy, Drug: Bevacizumab | Intervention Type: DRUG; Name: Chemotherapy; Assigned to Arm(s): Chemotherapy, Chemotherapy + Bevacizumab | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Chemotherapy + Bevacizumab

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Resistance Training in Radically Treated Respiratory Cancer Patients: a Prospective Randomized Multicenter Study
Brief Summary: The first part of the study is an observational part. In eligible patients with early stage respiratory cancer, the primary and secondary endpoints will be evaluated before and after their scheduled radical cancer therapy. The measured variables, include a blood sample, pulmonary function tests, level of dyspnea, exercise tests, measurement of body composition, respiratory and peripheral muscle force, health related quality of life and psychological status. Only registered participants having completed a radical treatment and having either less than 70% of the predicted normal value of the quadriceps force (QF) or a decrease of more than 10% predicted value of the QF between pre-and post radical treatment, will be allowed to participate to the second part of the study. These patients will then be randomized in three groups. Group A, the control group, will have the usual care and follow up according to clinical symptoms. Group B will be offered a conventional resistance training program (CRT), and group C, will be offered a whole body vibration resistance training (WBV) on the FITVIBE-platform. All previous variables will be measured after 6 and 12 weeks of training.


Options:
A: Arm Label: Resistance training; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Resistance training
B: Arm Label: Exercise Intervention Program (EIP); Type: EXPERIMENTAL; Interventions: Behavioral: Exercise Intervention, Other: Care-Management-Phone-Calls | Arm Label: Care-Management-Phone-Calls (CMPC); Type: ACTIVE_COMPARATOR; Interventions: Other: Care-Management-Phone-Calls | Intervention Type: BEHAVIORAL; Name: Exercise Intervention; Assigned to Arm(s): Exercise Intervention Program (EIP) | Intervention Type: OTHER; Name: Care-Management-Phone-Calls; Assigned to Arm(s): Care-Management-Phone-Calls (CMPC), Exercise Intervention Program (EIP)
C: Arm Label: Control - usual care; Type: OTHER; Interventions: Other: Usual care | Arm Label: Exercise + usual care; Type: OTHER; Interventions: Other: Usual care, Other: Exercise | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Control - usual care, Exercise + usual care | Intervention Type: OTHER; Name: Exercise; Assigned to Arm(s): Exercise + usual care
D: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional resistance training | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Other: Whole body vibration resistance training | Intervention Type: OTHER; Name: Conventional resistance training; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: Whole body vibration resistance training; Assigned to Arm(s): 3

Answer: D